Court Freezes Trump’s Rule Banning Pharma Rebates to PBMs

The Biden administration and Pharmaceutical Care Management Association (PCMA), the trade association for pharmaceutical benefit managers (PBMs), have agreed to postpone, from January 1, 2022, to January 1, 2023, the effective date of the Trump administration rule eliminating safe harbor

Read More »

340B Report Publisher/CEO: It Will Take Time for Contract Pharmacy Battle to Play Out

Recent developments in federal court bode well for 340B providers trying to restore access to 340B pricing in the contract pharmacy setting, 340B Report Publisher and CEO Ted Slafsky’s take in his latest column for the Omnicell blog

The battle in the courts among providers, drug manufacturers, and health officials over 340B contract pharmacy likely will take time to play out, 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell (a 340B Report

Read More »

HHS Asks Court to Toss Out Hospitals’ 340B Contract Pharmacy Lawsuit

The lawsuit against HHS by 340B hospitals is just one of several underway over drug manufacturers’ denials of 340B pricing on drugs dispensed by contract pharmacies. | Source: Shutterstock

Outgoing U.S. Health and Human Services (HHS) Secretary Alex Azar last week asked a federal district judge to dismiss a lawsuit against him and his department by 340B hospitals over HHS’s enforcement of its 340B contract pharmacy requirements for drug

Read More »

Health Centers File 340B Dispute Resolution Petitions Against Drug Manufacturers

The National Association of Community Health Centers (NACHC) last night on its members’ behalf asked a new federal 340B program administrative dispute resolution (ADR) panel to order drug manufacturers Eli Lilly and Co., Sanofi, and AstraZeneca to lift all “qualifications,

Read More »

Lilly Asks Court to Shield it From “Crippling” 340B Sanctions

Drug manufacturer Eli Lilly and Co. told a court this week that HHS has placed it in the "untenable position of offering 340B discounts that are not required by the statute or else facing crippling financial sanctions." | Source: Shutterstock

340B program stakeholders are still digesting drug manufacturers AstraZeneca, Eli Lilly and Co., and Sanofi’s Jan. 12 lawsuits to block federal sanctions over their decisions to stop or impose conditions on 340B discounts on drugs dispensed by contract pharmacies.

Read More »

AstraZeneca, Lilly, and Sanofi Sue HHS to Block Requirement To Give 340B Discounts To Contract Pharmacies

AstraZeneca, Eli Lilly and Co., and Sanofi sued HHS in defense of their 340B contract actions just hours before covered entities could begin challenging those actions in a new 340B administrative dispute resolution process. | Source: Shutterstock

In a major escalation of the fight over 340B contract pharmacy, drug manufacturer AstraZeneca late yesterday asked a federal court to declare that it “is not required to offer 340B discounts to contract pharmacies.”

As we went to press, we

Read More »

Breaking News

BREAKING: HHS’s Top Lawyer Says Pharma’s 340B Contract Pharmacy Actions Are at Odds with the Law

“Certain manufacturers’ newfound and unilateral refusal to sell [340B] drugs through contract pharmacies is at odds with the structure and intended operation of the [340B] statute,” HHS General Counsel Robert Charrow said in an advisory opinion late today. | Source:
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live